Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A randomized phase II study with NIVOlumab or continuation of therapy as an early SWITCH approach in patients with advanced or metastatic renal cell carcinoma (RCC) and disease control after 3 months of treatment with a tyrosine kinase inhibitor

Next Previous
X
Search
Trial Profile

A randomized phase II study with NIVOlumab or continuation of therapy as an early SWITCH approach in patients with advanced or metastatic renal cell carcinoma (RCC) and disease control after 3 months of treatment with a tyrosine kinase inhibitor

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 29 Feb 2024

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Nivolumab (Primary) ; Pazopanib; Sunitinib
  • Indications Renal cell carcinoma
  • Focus Therapeutic Use
  • Acronyms NIVOSWITCH

    • Most Recent Events

    • 24 Oct 2023 Results of exploratory Subgroup analysis investigating predictive value of the PD-L1 status, presented at the 48th European Society for Medical Oncology Congress
    • 18 Feb 2023 Results (n=39) investigating the predictive value of PD-L1 in plasma and on extracellular vesicles (EV) from plasma in the Nivoswitch trial. presented at the 2023 Genitourinary Cancers Symposium
    • 13 Apr 2021 Planned End Date changed from 1 Dec 2021 to 1 Sep 2021.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top